Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 79 years of age, inclusive~* Chronic Kidney Disease Stage 3 or Stage 4~* Hemoglobin (Hgb) \< 10.5 g/dl~* TSAT \> 20% and CBC indicating normocytic red blood cell morphology~Key Exclusion Criteria:~* BMI \> 40~* Red blood cell transfusion within 12 weeks.~* Androgen therapy within the previous 21 days prior to study dosing~* Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 10 weeks prior to the Screening visit~* Participants meeting the criteria of ESA resistance within the previous 4 months~* Individual doses of intravenous iron of 250 mg or larger within the past 21 days~* AST or ALT \>1.8x ULN.~* Alkaline phosphatase \>2x ULN.~* Total bilirubin \>1.5x ULN.~* Uncontrolled hypertension~* New York Heart Association Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).